A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-01

AUTHORS

R L Jones, G Walsh, S Ashley, S Chua, R Agarwal, M O'Brien, S Johnston, I E Smith

ABSTRACT

Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin)C given by conventional or accelerated schedules as neoadjuvant or adjuvant chemotherapy for early breast cancer. Furthermore, the relative toxicity of doxorubicin and epirubicin remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600 mg m(-2) in combination with doxorubicin 60 mg m(-2) (AC) vs epirubicin 90 mg m(-2) (EC) 3 weekly vs the same regimens administered every 2 weeks with pegfilgrastim (G-CSF). A total of 126 patients were treated, 42 with standard AC, 42 with accelerated AC, 19 with standard EC and 23 with accelerated EC. Significantly more grade 3/4 day one neutropenia was seen with standard (6/61, 10%) compared to accelerated (0/65,) regimens (P=0.01). A trend towards more neutropenic sepsis was seen in the combined standard and accelerated AC arms (12/84, 14%) compared to the combined EC arms (1/42, 2%), P=0.06. Falls in left ventricular ejection fraction were not increased with accelerated treatment. Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules. More... »

PAGES

305

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6604862

DOI

http://dx.doi.org/10.1038/sj.bjc.6604862

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031841194

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19165198


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Ductal, Breast", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Lobular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epirubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Filgrastim", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polyethylene Glycols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recombinant Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jones", 
        "givenName": "R L", 
        "id": "sg:person.01110361365.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Walsh", 
        "givenName": "G", 
        "id": "sg:person.0703557700.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703557700.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ashley", 
        "givenName": "S", 
        "id": "sg:person.016055156132.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016055156132.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chua", 
        "givenName": "S", 
        "id": "sg:person.0737666052.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737666052.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agarwal", 
        "givenName": "R", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Royal Marsden NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.5072.0", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O'Brien", 
        "givenName": "M", 
        "id": "sg:person.011127671322.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011127671322.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK", 
            "Institute of Cancer Research, Fulham Road, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnston", 
        "givenName": "S", 
        "id": "sg:person.013410565122.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013410565122.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.18886.3f", 
          "name": [
            "Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK", 
            "Institute of Cancer Research, Fulham Road, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "I E", 
        "id": "sg:person.016301514162.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016301514162.37"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21886", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006062235"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.5391", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020781072"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/dji398", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032079309"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.09.081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203847"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2000.18.20.3558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074712511"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.3.602", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074750662"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1990.8.9.1483", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1078467451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082545541", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-01", 
    "datePublishedReg": "2009-01-01", 
    "description": "Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin)C given by conventional or accelerated schedules as neoadjuvant or adjuvant chemotherapy for early breast cancer. Furthermore, the relative toxicity of doxorubicin and epirubicin remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600 mg m(-2) in combination with doxorubicin 60 mg m(-2) (AC) vs epirubicin 90 mg m(-2) (EC) 3 weekly vs the same regimens administered every 2 weeks with pegfilgrastim (G-CSF). A total of 126 patients were treated, 42 with standard AC, 42 with accelerated AC, 19 with standard EC and 23 with accelerated EC. Significantly more grade 3/4 day one neutropenia was seen with standard (6/61, 10%) compared to accelerated (0/65,) regimens (P=0.01). A trend towards more neutropenic sepsis was seen in the combined standard and accelerated AC arms (12/84, 14%) compared to the combined EC arms (1/42, 2%), P=0.06. Falls in left ventricular ejection fraction were not increased with accelerated treatment. Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.bjc.6604862", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "100"
      }
    ], 
    "name": "A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer", 
    "pagination": "305", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "97af4e0e87416996a130c6906b17307096053aee90d3a89a0abb02ed43f89d5d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19165198"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0370635"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6604862"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031841194"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6604862", 
      "https://app.dimensions.ai/details/publication/pub.1031841194"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T15:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8664_00000425.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://www.nature.com/articles/6604862"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604862'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604862'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604862'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604862'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      68 URIs      50 LITERALS      38 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6604862 schema:about N010d9609ab554e338003e44b8370acf4
2 N12d9891ea00c471ea5891dc9952c0a26
3 N135999cc61524188ba4533bb6785b30b
4 N183eb209fe0b42fcb30b97c8b9e5c0b9
5 N3310656998a54b5a9f6bed1630945a39
6 N46ee99cde0f9499abb2376dcdd74e281
7 N49edc44a98ae492fbbf61ea84180bad4
8 N52dc7def397b4bdbab7c30f06a085bb2
9 N57b005019320443c952b4bb469dd4fbf
10 N5c7e767788c74295a6f7fbb7631c6925
11 N682b2564284842da963e236cd0f43fba
12 N7c74b4770ade409e868c955e86fc2234
13 N7e57d6cbe2de4873bc0f409d4b0aa603
14 N8668464183c8444c9d133125c4398ea6
15 N86709ba0d5b54268b230ffef47df2980
16 N88e653e7e4394180a56cc11881d55776
17 N8dc4ccd5b64f4878a2ececfdc5652545
18 N9fd23c8c92fd456db11a0214e7b5e5ae
19 Naf8f1ec41dd0421e8eaf7ba23c2389d9
20 Nb62071566a604b1ea0e825f86e333887
21 Nb7707336dc2f4187b9bdfa2a9f65b13d
22 Nb942fe9d78ed468da183aa5db41d27b6
23 Nba2095532e9b44119a5320d206bc4bfc
24 Nc79e7d8a42dc48bb8a6a54eb538c9604
25 Ncaa768be77a04c5099e430f0381d8e9e
26 Nd2c8669716924441b813a937554c82cd
27 Nd4d50162c07d4970b9db4a10cea151c2
28 Nd84d0d9c19a947e2a5f167553ffe7ced
29 Ndc3a3e83b46e4c72a4a3a7d00a517895
30 anzsrc-for:11
31 anzsrc-for:1112
32 schema:author N3318aec7dd494a6fb958666fadd1766b
33 schema:citation https://app.dimensions.ai/details/publication/pub.1082545541
34 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
35 https://doi.org/10.1002/cncr.21886
36 https://doi.org/10.1016/s0140-6736(05)66544-0
37 https://doi.org/10.1093/jnci/dji398
38 https://doi.org/10.1200/jco.1990.8.9.1483
39 https://doi.org/10.1200/jco.2000.18.20.3558
40 https://doi.org/10.1200/jco.2001.19.3.602
41 https://doi.org/10.1200/jco.2003.09.081
42 https://doi.org/10.1200/jco.2006.06.5391
43 schema:datePublished 2009-01
44 schema:datePublishedReg 2009-01-01
45 schema:description Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin)C given by conventional or accelerated schedules as neoadjuvant or adjuvant chemotherapy for early breast cancer. Furthermore, the relative toxicity of doxorubicin and epirubicin remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600 mg m(-2) in combination with doxorubicin 60 mg m(-2) (AC) vs epirubicin 90 mg m(-2) (EC) 3 weekly vs the same regimens administered every 2 weeks with pegfilgrastim (G-CSF). A total of 126 patients were treated, 42 with standard AC, 42 with accelerated AC, 19 with standard EC and 23 with accelerated EC. Significantly more grade 3/4 day one neutropenia was seen with standard (6/61, 10%) compared to accelerated (0/65,) regimens (P=0.01). A trend towards more neutropenic sepsis was seen in the combined standard and accelerated AC arms (12/84, 14%) compared to the combined EC arms (1/42, 2%), P=0.06. Falls in left ventricular ejection fraction were not increased with accelerated treatment. Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree true
49 schema:isPartOf N920adca579394a37b84ad443d9a2b41b
50 Nf67385290ec2468891e5280e344fc2b5
51 sg:journal.1017082
52 schema:name A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
53 schema:pagination 305
54 schema:productId N164f7730b01a4a2a873101c485b872b3
55 N7d5fb690311440c9b93a982a940cd860
56 Na4d02e28c6df4c3980487d2d0ce2fb84
57 Nd3fa1c1059064e5db22bfdbd2dd8efcb
58 Nde311186c9aa470b8e89b2a8eb8602de
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031841194
60 https://doi.org/10.1038/sj.bjc.6604862
61 schema:sdDatePublished 2019-04-10T15:38
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nd208eb450d8c46d0ba17e195d48c10ac
64 schema:url https://www.nature.com/articles/6604862
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N010d9609ab554e338003e44b8370acf4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Epirubicin
70 rdf:type schema:DefinedTerm
71 N12d9891ea00c471ea5891dc9952c0a26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Neoadjuvant Therapy
73 rdf:type schema:DefinedTerm
74 N135999cc61524188ba4533bb6785b30b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Drug Therapy, Combination
76 rdf:type schema:DefinedTerm
77 N164f7730b01a4a2a873101c485b872b3 schema:name pubmed_id
78 schema:value 19165198
79 rdf:type schema:PropertyValue
80 N183eb209fe0b42fcb30b97c8b9e5c0b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Treatment Outcome
82 rdf:type schema:DefinedTerm
83 N24381df408334e80966151e1e15c3e5d rdf:first sg:person.011127671322.23
84 rdf:rest N9bad0a5572204b9ba0618898bd04a61b
85 N279b8f252af34f199c4a5dda1f8c96a7 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
86 schema:familyName Agarwal
87 schema:givenName R
88 rdf:type schema:Person
89 N3310656998a54b5a9f6bed1630945a39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Aged
91 rdf:type schema:DefinedTerm
92 N3318aec7dd494a6fb958666fadd1766b rdf:first sg:person.01110361365.31
93 rdf:rest N3d93c4d5894249d7babda372fd389e01
94 N3d93c4d5894249d7babda372fd389e01 rdf:first sg:person.0703557700.99
95 rdf:rest N5134b2a0bed3497880e04c523b159a4a
96 N46ee99cde0f9499abb2376dcdd74e281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Maximum Tolerated Dose
98 rdf:type schema:DefinedTerm
99 N49edc44a98ae492fbbf61ea84180bad4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Carcinoma, Lobular
101 rdf:type schema:DefinedTerm
102 N5134b2a0bed3497880e04c523b159a4a rdf:first sg:person.016055156132.72
103 rdf:rest Ndcaea73a9cab48548795cda491c57ca7
104 N52dc7def397b4bdbab7c30f06a085bb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N57b005019320443c952b4bb469dd4fbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Neoplasm Staging
109 rdf:type schema:DefinedTerm
110 N5c7e767788c74295a6f7fbb7631c6925 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cyclophosphamide
112 rdf:type schema:DefinedTerm
113 N5d6b677e0b4240d08f3542b5ba43a10a rdf:first N279b8f252af34f199c4a5dda1f8c96a7
114 rdf:rest N24381df408334e80966151e1e15c3e5d
115 N682b2564284842da963e236cd0f43fba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Survival Rate
117 rdf:type schema:DefinedTerm
118 N7c74b4770ade409e868c955e86fc2234 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Breast Neoplasms
120 rdf:type schema:DefinedTerm
121 N7d5fb690311440c9b93a982a940cd860 schema:name dimensions_id
122 schema:value pub.1031841194
123 rdf:type schema:PropertyValue
124 N7e57d6cbe2de4873bc0f409d4b0aa603 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 N8668464183c8444c9d133125c4398ea6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Carcinoma, Ductal, Breast
129 rdf:type schema:DefinedTerm
130 N86709ba0d5b54268b230ffef47df2980 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Recombinant Proteins
132 rdf:type schema:DefinedTerm
133 N88e653e7e4394180a56cc11881d55776 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Heart
135 rdf:type schema:DefinedTerm
136 N8dc4ccd5b64f4878a2ececfdc5652545 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Feasibility Studies
138 rdf:type schema:DefinedTerm
139 N920adca579394a37b84ad443d9a2b41b schema:volumeNumber 100
140 rdf:type schema:PublicationVolume
141 N9aff54cbb86740e5886aaf57e7547b15 rdf:first sg:person.016301514162.37
142 rdf:rest rdf:nil
143 N9bad0a5572204b9ba0618898bd04a61b rdf:first sg:person.013410565122.88
144 rdf:rest N9aff54cbb86740e5886aaf57e7547b15
145 N9fd23c8c92fd456db11a0214e7b5e5ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adult
147 rdf:type schema:DefinedTerm
148 Na4d02e28c6df4c3980487d2d0ce2fb84 schema:name nlm_unique_id
149 schema:value 0370635
150 rdf:type schema:PropertyValue
151 Naf8f1ec41dd0421e8eaf7ba23c2389d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Pilot Projects
153 rdf:type schema:DefinedTerm
154 Nb62071566a604b1ea0e825f86e333887 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Chemotherapy, Adjuvant
156 rdf:type schema:DefinedTerm
157 Nb7707336dc2f4187b9bdfa2a9f65b13d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Middle Aged
159 rdf:type schema:DefinedTerm
160 Nb942fe9d78ed468da183aa5db41d27b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Granulocyte Colony-Stimulating Factor
162 rdf:type schema:DefinedTerm
163 Nba2095532e9b44119a5320d206bc4bfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Neutropenia
165 rdf:type schema:DefinedTerm
166 Nc79e7d8a42dc48bb8a6a54eb538c9604 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Doxorubicin
168 rdf:type schema:DefinedTerm
169 Ncaa768be77a04c5099e430f0381d8e9e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Filgrastim
171 rdf:type schema:DefinedTerm
172 Nd208eb450d8c46d0ba17e195d48c10ac schema:name Springer Nature - SN SciGraph project
173 rdf:type schema:Organization
174 Nd2c8669716924441b813a937554c82cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Antineoplastic Combined Chemotherapy Protocols
176 rdf:type schema:DefinedTerm
177 Nd3fa1c1059064e5db22bfdbd2dd8efcb schema:name readcube_id
178 schema:value 97af4e0e87416996a130c6906b17307096053aee90d3a89a0abb02ed43f89d5d
179 rdf:type schema:PropertyValue
180 Nd4d50162c07d4970b9db4a10cea151c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Prognosis
182 rdf:type schema:DefinedTerm
183 Nd84d0d9c19a947e2a5f167553ffe7ced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Patient Selection
185 rdf:type schema:DefinedTerm
186 Ndc3a3e83b46e4c72a4a3a7d00a517895 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Polyethylene Glycols
188 rdf:type schema:DefinedTerm
189 Ndcaea73a9cab48548795cda491c57ca7 rdf:first sg:person.0737666052.34
190 rdf:rest N5d6b677e0b4240d08f3542b5ba43a10a
191 Nde311186c9aa470b8e89b2a8eb8602de schema:name doi
192 schema:value 10.1038/sj.bjc.6604862
193 rdf:type schema:PropertyValue
194 Nf67385290ec2468891e5280e344fc2b5 schema:issueNumber 2
195 rdf:type schema:PublicationIssue
196 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
197 schema:name Medical and Health Sciences
198 rdf:type schema:DefinedTerm
199 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
200 schema:name Oncology and Carcinogenesis
201 rdf:type schema:DefinedTerm
202 sg:journal.1017082 schema:issn 0007-0920
203 1532-1827
204 schema:name British Journal of Cancer
205 rdf:type schema:Periodical
206 sg:person.01110361365.31 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
207 schema:familyName Jones
208 schema:givenName R L
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110361365.31
210 rdf:type schema:Person
211 sg:person.011127671322.23 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
212 schema:familyName O'Brien
213 schema:givenName M
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011127671322.23
215 rdf:type schema:Person
216 sg:person.013410565122.88 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
217 schema:familyName Johnston
218 schema:givenName S
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013410565122.88
220 rdf:type schema:Person
221 sg:person.016055156132.72 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
222 schema:familyName Ashley
223 schema:givenName S
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016055156132.72
225 rdf:type schema:Person
226 sg:person.016301514162.37 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
227 schema:familyName Smith
228 schema:givenName I E
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016301514162.37
230 rdf:type schema:Person
231 sg:person.0703557700.99 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
232 schema:familyName Walsh
233 schema:givenName G
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703557700.99
235 rdf:type schema:Person
236 sg:person.0737666052.34 schema:affiliation https://www.grid.ac/institutes/grid.5072.0
237 schema:familyName Chua
238 schema:givenName S
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0737666052.34
240 rdf:type schema:Person
241 https://app.dimensions.ai/details/publication/pub.1082545541 schema:CreativeWork
242 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1002/cncr.21886 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006062235
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1016/s0140-6736(05)66544-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001690029
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1093/jnci/dji398 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032079309
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1200/jco.1990.8.9.1483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1078467451
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1200/jco.2000.18.20.3558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074712511
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1200/jco.2001.19.3.602 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074750662
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1200/jco.2003.09.081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203847
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1200/jco.2006.06.5391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020781072
259 rdf:type schema:CreativeWork
260 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
261 schema:name Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
262 Institute of Cancer Research, Fulham Road, London, UK
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.5072.0 schema:alternateName Royal Marsden NHS Foundation Trust
265 schema:name Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...